With almost 250,000 new cases in the United states and about 1,380,000 new cases throughout the world, breast cancer is the most common female malignancy, but it is also one of the most lethal tumors (almost 41,000 deaths estimated in the US in 2016) [1] [2]. Countries of the developing world exhibit a much higher mortality rate compared to the Western world, primarily because of a delayed diagnosis and late initiation of treatment [2] [3] [4] [5]. Studies have identified that between 3-8 months may pass from the onset of symptoms to the diagnosis in the developing world, compared to 30-48 days in Western countries [4]. As the majority of breast cancer tumors start as glandular tumors (adenocarcinomas), the term adenocarcinoma of the breast can be used to describe two main types of tumors - lobular and ductal carcinomas [6]. Numerous risk factors have been evaluated in the pathogenesis of breast cancer, but exposure to ionizing radiation, use of exogenous ovarian hormones, and excessive alcohol consumption have emerged as the most important ones [3] [7]. The main symptom of breast cancer is the presence of a lump in the breast, which may be accompanied by edema (either locally or in the armpit, suggesting dissemination of the tumor into the proximal lymph nodes) [6]. In addition, localized pain, inversion or retraction of the nipple, breast tenderness and discomfort are reported [6]. Constitutional complaints (fatigue, malaise, weakness) and distant pain (suggesting metastatic spread) are seen in more advanced stages of the disease [8].

A detailed patient history and a complete physical examination are considered to be essential steps in the initial workup of breast cancer patients. During the patient interview, physicians should obtain key information about the onset and progression of symptoms and assess whether any of the mentioned risk factors (exposure to ionizing radiation, previous biopsies of the breast, use of oral contraceptives or post-menopausal hormonal supplements, and alcohol consumption are present [3]. A thorough family history, which may identify breast cancer or a history of other malignancies within the family, is also important [3]. The physical examination, however, is essential. A full inspection and palpation of both breasts is necessary in order to confirm the exact site of the mass, exclude enlargement of axillary lymph nodes, and evaluate the appearance of both the nipples (discharge, or anatomical changes such as inversion or retraction) and the surrounding skin (peau d'orange is a highly specific finding in advanced breast cancer where the skin resembles an orange peel) [3] [6]. Once a presumptive diagnosis is made based on clinical findings, imaging studies should be employed. Mammography is by many authors still regarded as the principal method for detection of lesions in the breast, and its use is indicated in all women who present with a palpable mass on physical examination [3] [9]. Additional procedures that can be used are magnetic resonance imaging (MRI) and ultrasonography, both used to assess the exact size and determine the tumor stage [3] [9] [10]. To determine the exact type of the tumor, a biopsy (either fine needle, core needle or excisional) is necessary [9] [11].

Treatment for adenocarcinoma of the breast depends on the stage and characteristics of the tumor. Options include surgery, radiation therapy, chemotherapy, hormone therapy, and targeted therapy. Surgery may involve a lumpectomy (removal of the tumor and some surrounding tissue) or mastectomy (removal of the entire breast). Radiation therapy is often used after surgery to eliminate any remaining cancer cells. Chemotherapy and hormone therapy are systemic treatments that target cancer cells throughout the body.

The prognosis for adenocarcinoma of the breast varies based on several factors, including the stage at diagnosis, tumor size, lymph node involvement, and the cancer's molecular characteristics. Early-stage cancers generally have a better prognosis, with high survival rates. Advances in treatment have significantly improved outcomes, but ongoing follow-up is essential to monitor for recurrence.

The exact cause of adenocarcinoma of the breast is not fully understood, but several risk factors have been identified. These include age, family history of breast cancer, genetic mutations (such as BRCA1 and BRCA2), hormonal factors, and lifestyle factors like alcohol consumption and obesity. Understanding these risk factors can help in assessing an individual's risk and implementing preventive measures.

Adenocarcinoma of the breast is the most common cancer among women worldwide, with varying incidence rates across different regions. It is more prevalent in developed countries, likely due to lifestyle and reproductive factors. While it primarily affects women, men can also develop breast cancer, though it is rare. The incidence increases with age, with most cases diagnosed in women over 50.

Adenocarcinoma of the breast arises from the uncontrolled growth of epithelial cells in the breast's glandular tissue. Genetic mutations and hormonal influences play a significant role in the development and progression of the disease. These changes can lead to the formation of a tumor, which may invade surrounding tissues and spread to other parts of the body (metastasis).

While not all cases of adenocarcinoma of the breast can be prevented, certain measures can reduce risk. These include maintaining a healthy weight, limiting alcohol intake, engaging in regular physical activity, and considering the risks and benefits of hormone replacement therapy. For those with a high genetic risk, such as BRCA mutation carriers, more intensive surveillance or preventive surgery may be recommended.

Adenocarcinoma of the breast is a common and potentially serious form of cancer that originates in the glandular tissue of the breast. Early detection through regular screening and awareness of symptoms is crucial for effective treatment. A multidisciplinary approach, including surgery, radiation, and systemic therapies, offers the best chance for a favorable outcome. Understanding risk factors and engaging in preventive measures can help reduce the incidence of this disease.

If you or someone you know is experiencing symptoms such as a breast lump, changes in breast appearance, or nipple discharge, it is important to seek medical evaluation. Early diagnosis and treatment are key to improving outcomes. Regular breast cancer screenings, such as mammograms, are recommended for women over 40 or earlier for those with a family history of breast cancer. Discuss your individual risk factors and screening schedule with your healthcare provider.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–2917.
3. Shah R, Rosso K, Nathanson SD. Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol. 2014;5(3):283-298.
4. Unger-Saldaña K. Challenges to the early diagnosis and treatment of breast cancer in developing countries. World J Clin Oncol. 2014;5(3):465-477.
5. Coleman MP, Quaresma M, Berrino F, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD) Lancet Oncol. 2008;9:730–756.
6. Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK. Various Types and Management of Breast Cancer: An Overview. J Adv Pharm Technol Res. 2010;1(2):109-126.
7. MacMahon B. Epidemiology and the causes of breast cancer. Int J Cancer. 2006;118(10):2373-2378.
8. Irvin W, Muss HB, Mayer DK. Symptom Management in Metastatic Breast Cancer. Oncologist. 2011;16(9):1203-1214.
9. Yip CH, Bhoo Pathy N, Teo SH. A review of breast cancer research in malaysia. Med J Malaysia. 2014;69 Suppl A:8-22.
10. Berg WA, Blume JD, Cormack JB, et al. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA. 2008;299:2151–2163.
11. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2008. CA Cancer J Clin. 2008;58:161–179.